The Clinical and Cellular Impact of RBMS2 on the Progression and Prognosis of Kidney Renal Clear Cell Carcinoma

Table 1

ccRCC patients’ characteristics and correlations with RBMS2 expression level.

Characteristics	Low expression of RBMS2	High expression of RBMS2	value
n	270	271
Gender, n (%)			0.092
Female	84 (15.5%)	103 (19%)
Male	186 (34.4%)	168 (31.1%)
Age, n (%)			0.035
≤60	122 (22.6%)	147 (27.2%)
>60	148 (27.4%)	124 (22.9%)
Serum calcium, n (%)			0.002
Low	90 (24.5%)	114 (31.1%)
Normal and elevated	98 (26.7%)	65 (17.7%)
Histologic grade, n (%)			<0.001
G1 and G2	96 (18%)	154 (28.9%)
G3 and G4	168 (31.5%)	115 (21.6%)
Pathologic T stage, n (%)			<0.001
T1 and T2	150 (27.7%)	200 (37%)
T3 and T4	120 (22.2%)	71 (13.1%)
Pathologic N stage, n (%)			0.400
N0	125 (48.4%)	117 (45.3%)
N1	10 (3.9%)	6 (2.3%)
Pathologic M stage, n (%)			<0.001
M0	201 (39.6%)	228 (44.9%)
M1	53 (10.4%)	26 (5.1%)
Pathologic stage, n (%)			<0.001
Stage I and stage II	138 (25.7%)	194 (36.1%)
Stage III and stage IV	129 (24%)	77 (14.3%)